GlaxoSmithKline (London, UK, www.gsk.com) has received another order from the US Department of Health and Human Services (HHS) for 22.5 million doses of bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines.
GlaxoSmithKline (London, UK, www.gsk.com) has received another order from the US Department of Health and Human Services (HHS) for 22.5 million doses of bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines. This is in addition to the 5 million doses of H5N1 bulk antigen ordered by the HHS in November 2006.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.